Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q3 FY23 results · Oct–Dec 2022
Ajanta Pharma reported revenue from operations of ₹971.77 crore (up 16.0% from Q3 FY22) and net profit of ₹134.51 crore (down 29.9% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 971.77 | 837.91 | +16.0% | 938.10 | +3.6% |
| Other income | 34.93 | 24.03 | +45.4% | 40.35 | −13.4% |
| Total income | 1,006.70 | 861.94 | +16.8% | 978.45 | +2.9% |
| Profit before tax | 168.34 | 230.94 | −27.1% | 203.00 | −17.1% |
| Net profit for the period | 134.51 | 191.78 | −29.9% | 156.60 | −14.1% |
| EPS, basic (₹) | 10.50 | 22.16 | not comparable | 12.22 | −14.1% |
| Net margin (%) | 13.8 | 22.9 | 16.7 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 874.89 | 808.58 | +8.2% | 837.23 | +4.5% |
| Other income | 30.51 | 27.90 | +9.4% | 78.37 | −61.1% |
| Total income | 905.40 | 836.48 | +8.2% | 915.60 | −1.1% |
| Profit before tax | 154.95 | 234.36 | −33.9% | 206.59 | −25.0% |
| Net profit for the period | 123.96 | 194.71 | −36.3% | 167.18 | −25.9% |
| EPS, basic (₹) | 9.67 | 22.50 | not comparable | 13.05 | −25.9% |
| Net margin (%) | 14.2 | 24.1 | 20.0 |
Consolidated
- Filed with BSE
- 02 Feb 2023, 15:45 IST
- Board meeting
- 01 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 Feb 2023, 15:45 IST
- Board meeting
- 01 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE